Molecular Pharmacology

Molecular Pharmacology is a journal of the American Society for Pharmacology and Experimental Therapeutics, published since 1965 and published by Elsevier from January 2025, applying structural biology, biochemistry, biophysics, physiology, genetics and molecular biology to basic pharmacological problems, with a 2025 impact factor of 3.0《Molecular Pharmacology》是美国实验药理学与治疗学会的期刊，1965 年创刊，并自 2025 年一月起由爱思唯尔代出版，以结构生物学、生物化学、生物物理学、生理学、遗传学与分子生物学方法研究基础药理学问题，2025 年影响因子为 3.0。

Scope

• It presents findings derived from the application of innovative structural biology, biochemistry, biophysics, physiology, genetics and molecular biology to basic pharmacological problems刊载运用创新性结构生物学、生物化学、生物物理学、生理学、遗传学与分子生物学于基础药理学问题的研究发现。
• It provides mechanistic insights that are broadly important for the fields of pharmacology and toxicology提供对药理学与毒理学领域具广泛意义的机制洞见。
• Relevant topics include molecular signalling and the mechanism of drug action, and chemical biology and drug discovery相关主题包括分子信号与药物作用机制，以及化学生物学与药物发现。
• Further topics are the structure of the drug-receptor complex, systems analysis of drug action, and drug transport and metabolism其它主题包括药物-受体复合物结构、药物作用的系统分析，以及药物转运与代谢。
• It accepts research articles, Mini-Reviews, Emerging Concepts and Perspectives接收研究论文、小综述、新兴概念与观点文。
• A Highlighted Trainee Authors feature spotlights an early-career author in each issue该刊设 Highlighted Trainee Authors 栏目，每期推举一位青年作者。

History

• It was founded in 1965, with volume 1, number 1 in July 1965, as the society's molecular pharmacology journal following The Journal of Pharmacology and Experimental Therapeutics of 1909该刊 1965 年创刊，第一卷第一期于 1965 年七月出版，是继 1909 年《The Journal of Pharmacology and Experimental Therapeutics》之后学会的分子药理学专业刊。^[1]
• It has had no name change该刊无更名史。
• It was published by the society from 1965 to 2024 and has been published by Elsevier from January 2025该刊 1965 年至 2024 年由学会自办出版，自 2025 年一月起改由爱思唯尔出版。
• Print issues ceased with volume 80, number 6 in 2011, and since then articles are published continuously online as soon as they are ready纸质版于 2011 年第八十卷第六期停印，此后文章一经就绪即在线连续出版。
• It has been indexed in MEDLINE since 1965, and its subjects include Pharmacology and Molecular Medicine该刊自 1965 年起被医学索引收录，学科包括药理学与分子医学。
• Its 2025 impact factor is 3.0, and articles published from one to five years ago are freely accessible其 2025 年影响因子为 3.0，发表后一年至五年的文章可免费获取。

Editors

• The Editor-in-Chief is John Tesmer, PhD, of the Department of Biological Sciences at Purdue University in West Lafayette, Indiana, United States, whose field is GPCRs, G-protein signalling and protein kinases现任主编为 John Tesmer，博士，供职于美国印第安纳州西拉法叶普渡大学生物科学系，研究方向为 GPCR、G 蛋白信号与蛋白激酶。
• The Deputy Editor-in-Chief is Martin C. Michel, MD, of Johannes Gutenberg University Mainz in Germany, working on cardiovascular and urological diseases副主编为 Martin C. Michel，医学博士，供职于德国美因茨约翰内斯古腾堡大学，研究心血管与泌尿系统疾病。
• The Ethics Editor is Michael Jarvis, the Mini-Reviews Editor is Adriano Marchese of the Medical College of Wisconsin, and the Emerging Concepts Editor is David Gewirtz of Virginia Commonwealth University伦理主编为 Michael Jarvis，小综述编辑为美国威斯康星医学院的 Adriano Marchese，新兴概念编辑为美国弗吉尼亚联邦大学的 David Gewirtz。
• The statistics editors are Martin C. Michel and Harvey Motulsky统计学编辑为 Martin C. Michel 与 Harvey Motulsky。
• Associate editors include Jerod Denton, Lakshmi Devi, Sudarshan Rajagopal and Joanne Wang, mostly based in the United States副编辑包括 Jerod Denton、Lakshmi Devi、Sudarshan Rajagopal 与 Joanne Wang，多在美国。
• An international editorial advisory board of about sixty members includes Nobel laureate Brian Kobilka, and accepted papers appear in Fast Forward within 48 hours约六十人的国际化顾问编委会包括诺贝尔化学奖得主 Brian Kobilka，录用稿件在 48 小时内于 Fast Forward 提前上线。